MAPT and Alzheimer disease: Consistent with previous work using these assays, levels of CSF p-tau181Lilly and p-tau217Lilly were progressively higher across both the AD continuum (i.e., moving from Aβ-positive CU through Aβ-positive AD dementia)14,15 and tau-PET Braak stages.14 Furthermore, in agreement with a previous study, we found that p-tau217Lilly had significantly higher correlations with Aβ and tau-PET as compared to p-tau181Lilly14 and extended this finding to show that the correlation was also significantly higher than for p-tau181Innotest, p-tau181Elecsys, and p-tau231ADx.